Search details
1.
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Oncologist
; 2024 May 08.
Article
in English
| MEDLINE | ID: mdl-38716772
2.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-38129136
3.
Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Int J Gynecol Cancer
; 33(4): 598-606, 2023 04 03.
Article
in English
| MEDLINE | ID: mdl-36707087
4.
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions.
Int J Gynecol Cancer
; 33(4): 431-443, 2023 04 03.
Article
in English
| MEDLINE | ID: mdl-36928097
5.
Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature review.
Int J Gynecol Cancer
; 2023 Nov 10.
Article
in English
| MEDLINE | ID: mdl-37949488
6.
Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence.
Int J Gynecol Cancer
; 33(5): 734-740, 2023 05 01.
Article
in English
| MEDLINE | ID: mdl-36759002
7.
Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Int J Cancer
; 151(10): 1791-1803, 2022 11 15.
Article
in English
| MEDLINE | ID: mdl-35695283
8.
Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience.
Int J Cancer
; 148(1): 170-177, 2021 01 01.
Article
in English
| MEDLINE | ID: mdl-32856727
9.
A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety.
Cancers (Basel)
; 16(1)2023 Dec 30.
Article
in English
| MEDLINE | ID: mdl-38201619
10.
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Int J Gynecol Cancer
; 22(5): 792-800, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22635029
11.
Simple conization and lymphadenectomy for the conservative treatment of stage IB1 cervical cancer. An Italian experience.
Gynecol Oncol
; 123(3): 557-60, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-21907396
12.
Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.
Int J Radiat Oncol Biol Phys
; 101(3): 650-660, 2018 07 01.
Article
in English
| MEDLINE | ID: mdl-29893277
13.
Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
Anticancer Res
; 37(9): 5241-5248, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28870960
14.
Ovarian cancer.
Crit Rev Oncol Hematol
; 60(2): 159-79, 2006 Nov.
Article
in English
| MEDLINE | ID: mdl-17018256
15.
A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Cancer Epidemiol Biomarkers Prev
; 15(10): 1914-9, 2006 Oct.
Article
in English
| MEDLINE | ID: mdl-17035399
16.
Neoadjuvant chemotherapy in cervical cancer: an update.
Expert Rev Anticancer Ther
; 15(10): 1171-81, 2015.
Article
in English
| MEDLINE | ID: mdl-26402247
17.
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer.
J Natl Cancer Inst
; 103(4): 347-51, 2011 Feb 16.
Article
in English
| MEDLINE | ID: mdl-21217084
18.
Management of ovarian stromal cell tumors.
J Clin Oncol
; 25(20): 2944-51, 2007 Jul 10.
Article
in English
| MEDLINE | ID: mdl-17617526
19.
Chemo-conization in early cervical cancer.
Gynecol Oncol
; 107(1 Suppl 1): S125-6, 2007 Oct.
Article
in English
| MEDLINE | ID: mdl-17727935
Results
1 -
19
de 19
1
Next >
>>